J Stroke.  2023 May;25(2):315-319. 10.5853/jos.2022.03391.

Prevalence of Amyloid Cerebral Deposits and Cognitive Outcome After Stroke: The IDEA3 Study

• Godefroy O
• Barbay M
• Martin J
• Shields T
• Lamy C
• Courselle-Arnoux A
• Canaple S
• Leclercq C
• Roussel M
• Meyer ME
• Marchal E
• Wollenweber FA
• The IDEA3 Study Group

• KMID: 2542485
• DOI: http://doi.org/10.5853/jos.2022.03391

Figure

• 

  Figure 1. Z scores (standard error) of the five cognitive domains according to amyloid status.

Reference

References

1. Barbay M, Diouf M, Roussel M, Godefroy O; GRECOGVASC study group. Systematic review and meta-analysis of prevalence in post-stroke neurocognitive disorders in hospital-based studies. Dement Geriatr Cogn Disord. 2018; 46:322–334.

2. Tatemichi TK, Desmond DW, Stern Y, Paik M, Sano M, Bagiella E. Cognitive impairment after stroke: frequency, patterns, and relationship to functional abilities. J Neurol Neurosurg Psychiatry. 1994; 57:202–207.

3. Rockwood K, Wentzel C, Hachinski V, Hogan DB, MacKnight C, McDowell I. Prevalence and outcomes of vascular cognitive impairment. Vascular cognitive impairment investigators of the Canadian Study of Health and Aging. Neurology. 2000; 54:447–451.

4. Haley WE, Roth DL, Kissela B, Perkins M, Howard G. Quality of life after stroke: a prospective longitudinal study. Qual Life Res. 2011; 20:799–806.

5. Desmond DW, Moroney JT, Bagiella E, Sano M, Stern Y. Dementia as a predictor of adverse outcomes following stroke: an evaluation of diagnostic methods. Stroke. 1998; 29:69–74.

6. Tatemichi TK, Desmond DW, Mayeux R, Paik M, Stern Y, Sano M, et al. Dementia after stroke: baseline frequency, risks, and clinical features in a hospitalized cohort. Neurology. 1992; 42:1185–1193.

7. Kokmen E, Whisnant JP, O’Fallon WM, Chu CP, Beard CM. Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960-1984). Neurology. 1996; 46:154–159.

8. Pohjasvaara T, Erkinjuntti T, Ylikoski R, Hietanen M, Vataja R, Kaste M. Clinical determinants of poststroke dementia. Stroke. 1998; 29:75–81.

9. Mok VCT, Lam BYK, Wang Z, Liu W, Au L, Leung EYL, et al. Delayed-onset dementia after stroke or transient ischemic attack. Alzheimers Dement. 2016; 12:1167–1176.

10. Wollenweber FA, Därr S, Müller C, Duering M, Buerger K, Zietemann V, et al. Prevalence of amyloid positron emission tomographic positivity in poststroke mild cognitive impairment. Stroke. 2016; 47:2645–2648.

11. Hagberg G, Ihle-Hansen H, Fure B, Thommessen B, Ihle-Hansen H, Øksengård AR, et al. No evidence for amyloid pathology as a key mediator of neurodegeneration post-stroke - a seven-year follow-up study. BMC Neurol. 2020; 20:174.

12. Koenig LN, McCue LM, Grant E, Massoumzadeh P, Roe CM, Xiong C, et al. Lack of association between acute stroke, poststroke dementia, race, and β-amyloid status. Neuroimage Clin. 2021; 29:102553.

13. Barbay M, Taillia H, Nédélec-Ciceri C, Bompaire F, Bonnin C, Varvat J, et al. Prevalence of poststroke neurocognitive disorders using National Institute of Neurological Disorders and Stroke-Canadian Stroke Network, VASCOG criteria (vascular behavioral and cognitive disorders), and optimized criteria of cognitive deficit. Stroke. 2018; 49:1141–1147.

14. Godefroy O, Gibbons L, Diouf M, Nyenhuis D, Roussel M, Black S, et al. Validation of an integrated method for determining cognitive ability: implications for routine assessments and clinical trials. Cortex. 2014; 54:51–62.

15. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir F 18). J Nucl Med. 2010; 51:913–920.

16. Sahathevan R, Linden T, Villemagne VL, Churilov L, Ly JV, Rowe C, et al. Positron emission tomographic imaging in stroke: cross-sectional and follow-up assessment of amyloid in ischemic stroke. Stroke. 2016; 47:113–119.